ArticleJournal of nanobiotechnology2026
Plasmonic platinum-tipped gold nanorods for tumor-targeted multimodal imaging diagnosis and NIR-II photothermal-catalytic-immuno synergetic therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dumbbell-Structured Plasmonic-Enhanced Optical Nanoprobes Boosting Photo-Magnetic-Acoustic Multimodal Imaging-Guided Photodynamic-Photothermal Synergistic Treatment and Immunogenic Death in Nasopharyngeal Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Recent Advances in Nanomedicine for Targeted Phototherapy in Head and Neck Cancer.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To address the severe side effects of radiotherapy, high recurrence and metastasis rates, and the limited efficacy of single-mode phototherapy in treating nasopharyngeal carcinoma (NPC), this study reports the development of dumbbell-shaped composite optical nanoprobes enabling multimodal optical imaging-guided NIR-II photothermal-catalytic-immuno synergistic therapy. The nanoprobes consist of platinum nanocluster (PtNCs)-tipped gold nanorods (AuNRs) with surface-loaded indocyanine green (ICG) and NPC-targeting peptides (APINs), that exhibit excellent NIR-II absorption properties, photothermal conversion efficiency, and photoacoustic imaging capability. Moreover, the plasmonic resonance effect of AuNRs enhances the catalytic activity of PtNCs at both ends of the AuNR, promoting the generation of reactive oxygen species and thereby synergistically inducing tumor cell destruction. The APINs can be efficiently internalized by NPC cells, present superior biocompatibility, and effectively induce cell killing under 1064 nm laser irradiation. Further in vivo experiments validate the NPC-targeting multimodal imaging capability and tumor inhibition is achieved post treatments, accompanied by the induction of immunogenic cell death. At 18 days post-administration, NPC-xenografted tumor recurrence and metastasis are significantly suppressed. This approach offers a new optical therapeutic model for precise NPC theranostics, with potential clinical application values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.